Tian Danning, Lai Yuping
School of Life Sciences, East China Normal University, Shanghai, China.
Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, East China Normal University, Shanghai, China.
JID Innov. 2022 Mar 9;2(3):100116. doi: 10.1016/j.xjidi.2022.100116. eCollection 2022 May.
Over the past decades, tremendous success in the treatment of psoriasis has been achieved using biologics, such as neutralizing antibodies against TNF/TNFR, IL-23, and IL-17A/IL-17RA. Although psoriatic skin lesions appear to resolve after treatment with these biologics, lesions often recur after therapy is discontinued or during therapy. Memory T cells residing in the skin have been considered as the major driver of psoriasis relapse. However, whether structural cells in the skin such as keratinocytes and fibroblasts are involved in the relapse of psoriasis is unknown. In this review, we outline the therapeutic rationale of biologics used in the treatment of psoriasis, summarize different clinical features of psoriasis relapse on the basis of preclinical and clinical data, and specifically discuss how memory T cells and structural cells in the skin are involved in psoriasis relapse. Finally, we discuss the future challenges in the basic or clinical research on psoriasis.
在过去几十年中,使用生物制剂治疗银屑病取得了巨大成功,例如针对TNF/TNFR、IL-23以及IL-17A/IL-17RA的中和抗体。尽管使用这些生物制剂治疗后银屑病皮损似乎消退,但在治疗中断后或治疗期间皮损常常复发。驻留在皮肤中的记忆T细胞被认为是银屑病复发的主要驱动因素。然而,皮肤中的结构细胞如角质形成细胞和成纤维细胞是否参与银屑病复发尚不清楚。在本综述中,我们概述了用于治疗银屑病的生物制剂的治疗原理,基于临床前和临床数据总结了银屑病复发的不同临床特征,并特别讨论了皮肤中的记忆T细胞和结构细胞如何参与银屑病复发。最后,我们讨论了银屑病基础或临床研究中的未来挑战。